Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
Webcast
0.25 AMA PRA Category 1 Credit™ ...OVERVIEW
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review is organized by Global Oncology Academy (GOA).
Publication Dates
Release Date: 03/14/2024
Expiration Date: 03/14/2025
Description:
Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them in your practice? Join Drs. Costello and Lonial as they explore a case study that demonstrates how to select patients, prepare them for treatment, and effectively manage treatment-related side effects.
Learning Objectives:
After participating in this educational activity, participants should be better able to:
- Employ strategies, including prophylaxis and step-up dosing, in treatment planning for relapsed and refractory multiple myeloma (RRMM) to prevent adverse events associated with bispecific antibody treatment.
- Collaborate with local hospitals and multiple myeloma specialty care centers to prevent, identify, and manage cytokine release syndrome in patients with RRMM undergoing treatment with a bispecific antibody.
ACCREDITATION & CREDITS
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until March 14, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .25 contact hours/0.025 CEUs of pharmacy contact hours.1
TARGET AUDIENCE
PhysicianPharmacistEmergency Medicine PhysiciansOncologistsHospitalistHematologistAdvanced Practice CliniciansPathologistsAdvanced Practice ProvidersSPECIALITIES
OncologyHematopathology
Quick Links